Statement: More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event.
Primary_evidence: Adverse Events 1:   Total: 31/52 (59.62%)   Febrile neutropenia 2/52 (3.85%)   Left ventricular dysfunction 2/52 (3.85%)   Sinus tachycardia 1/52 (1.92%)   Congenital arterial malformation 1/52 (1.92%)   Diarrhoea 5/52 (9.62%)   Salivary hypersecretion 1/52 (1.92%)   Enteritis 1/52 (1.92%)   Abdominal pain 1/52 (1.92%)   Vomiting 1/52 (1.92%)   Stomatitis 1/52 (1.92%)   Haematemesis 1/52 (1.92%)
Secondary_evidence: Adverse Events 1:   Total: 57/57 (100.00%)   Dry eyes  13/33 (39.39%)   Heartburn  9/33 (27.27%)   Nausea after the CT (before day 7)  57/57 (100.00%)   Herpetic eruption  0/33 (0.00%)   Dry skin  15/33 (45.45%)   Alopecia  57/57 (100.00%) Adverse Events 2:   Total: 23/23 (100.00%)   Dry eyes  2/11 (18.18%)   Heartburn  2/11 (18.18%)   Nausea after the CT (before day 7)  23/23 (100.00%)   Herpetic eruption  3/11 (27.27%)   Dry skin  9/11 (81.82%)   Alopecia  23/23 (100.00%)